Pharm'Up 
Piramal Critical Care (PCC) has officially finalized its acquisition of the Kenalog® product line, a move that significantly broadens its portfolio of specialized hospital medicines. This legacy brand, known for its efficacy in treating various inflammatory conditions, is currently marketed in 15 countries under several recognized names, including Kenacort®, Trigon®, and Adcortyl®.
By integrating Kenalog® into its existing Complex Generics division, Piramal aims to leverage its expansive distribution network—which spans over 6,000 hospitals across more than 100 countries. The company expects this acquisition to drive substantial growth, particularly within the high-demand markets of the United States, Europe, and Asia Pacific, while maintaining its rigorous focus on pharmaceutical quality and regulatory compliance.
About the Author
